| |
|
Product Name:
|
1S28
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Bacteria Classification: Bacillaceae, Bacillus
Species: Bacillus subtilis
Strain: 1S28 (also referred to as Z31)1
|
|
Additional Information:
|
B. subtilis is a Gram-positive, sporulating bacillus commonly found in the soil. It has also been isolated from the gastrointestinal tract of humans and animals.5,6 B. subtilis is generally regarded as non-pathogenic, but has been reported to cause human infections.7 B. subtilis is considered to be the model organism for Gram-positive bacteria, and is known as a hardy organism due its capabilities of sporulation, biofilm formation, motility and uptake of exogenous DNA.8,9 Its potential use as a probiotic and vaccine delivery method, as well as its ability to produce antibiotics and other useful enzymes, make it an important organism in the biotechnology industry.6,9,10,11
|
|
Material Provided:
|
Each vial contains approximately 0.5 mL of bacterial culture in Tryptic Soy broth supplemented with 10% glycerol.
Note: If homogeneity is required for your intended use, please purify prior to initiating work.
|
|
Packing/Storage:
|
NR-51333 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Media:
Tryptic Soy broth or equivalent
Tryptic Soy agar or equivalent
Incubation:
Temperature: 37°C
Atmosphere: Aerobic
Propagation:
1. Keep vial frozen until ready for use, then thaw.
2. Transfer the entire thawed aliquot into a single tube of broth.
3. Use several drops of the suspension to inoculate an agar slant and/or plate.
4. Incubate the tubes and plate at 37°C for 1 day.
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use.
Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.
While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.
This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.
|
References:
|
1. Coote, J. G. “Sporulation in Bacillus subtilis. Characterization of Oligosporogenous Mutants and Comparison of Their Phenotypes with Those of Asporogenous Mutants.” J. Gen. Microbiol. 71 (1972): 1-15. PubMed: 4625072.
2. Thomas, J. A., Personal Communication.
3. Kinney, D. M. and M. G. Bramucci. “Analysis of Bacillus subtilis Sporulation with Spore-Converting Bacteriophage PMB12.” J. Bacteriol. 145 (1981): 1281-1285. PubMed: 6782091.
4. Silver-Mysliwiec, T. H. and M. G. Bramucci. “Bacteriophage-Enhanced Sporulation: Comparison of Spore-Converting Bacteriophages PMB12 and SP10.” J. Bacteriol. 172 (1990): 1948-1953. PubMed: 2108128.
5. Porwal, S., et al. “Phylogeny in Aid of the Present and Novel Microbial Lineages: Diversity in Bacillus.” PLoS One 4 (2009): e4438. PubMed: 19212464.
6. Tam, N. K., et al. “The Intestinal Life Cycle of Bacillus subtilis and Close Relatives.” J. Bacteriol. 188 (2006): 2692-2700. PubMed: 16547057.
7. Logan, N. A. “Bacillus Species of Medical and Veterinary Importance.” J. Med. Microbiol. 25 (1988): 157-165. PubMed: 3279213.
8. Tan, I. S. and K. S. Ramamurthi. “Spore Formation in Bacillus subtilis.” Environ. Microbiol. Rep. 6 (2014): 212-225. PubMed: 24983526.
9. Cui, W., et al. “Exploitation of Bacillus subtilis as a Robust Workhorse for Production of Heterologous Proteins and Beyond.” World J. Microbiol. Biotechnol. 34 (2018): 145. PubMed: 30203131.
10. Ferreira, L. C., R. C. Ferreira and W. Schumann. “Bacillus subtilis as a Tool for Vaccine Development: From Antigen Factories to Delivery Vectors.” An. Acad. Bras. Cienc. 77 (2005): 113-124. PubMed: 15692682.
11. Pinchuk, I. V., et al. “Amicoumacin Antibiotic Production and Genetic Diversity of Bacillus subtilis Strains Isolated from Different Habitats.” Res. Microbiol. 153 (2002): 269-276. PubMed: 12160317.
|
|
Citation:
|
Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Bacillus subtilis, Strain 1S28, NR-51333.”
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|